You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石四藥集團(02005.HK):一季度純利增加14.6%至4.16億港元
格隆匯 04-16 16:35

格隆匯4月16日丨石四藥集團(02005.HK)發佈公吿,集團銷售主要在中國進行,並以人民幣計值,截至2024年3月31日止三個月,人民幣兑港元較2023年同期貶值約3.6%。因此,按港元計,集團截至2024年3月31日止三個月的未經審核營業額較2023年同期僅增加2.9%至約17.99億港元(2023年同期:約17.49億港元)。未經審核毛利增加2.3%至約10.31億港元(2023年同期:約10.08億港元)。未經審核毛利率約為57.3%,較2023年同期輕微下降0.3個百分點。未經審核公司股東應占溢利較2023年同期增加約14.6%至約4.16億港元(2023年同期:約3.63億港元)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account